A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
Status:
Terminated
Trial end date:
2018-04-12
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus
standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin
(PCN), or cefazolin) in the treatment of subjects with complicated Staphylococcus aureus (S.
aureus) bacteremia and SA right-sided infective endocarditis (SA-RIE).
Phase:
Phase 3
Details
Lead Sponsor:
Cumberland Pharmaceuticals Theravance Biopharma Antibiotics, Inc.